Home - Medical Policies - Alabama
- Advanced Imaging
- Autism Spectrum Mandate
- Behavioral Health
- Blue Advantage Policies
- Chronic Condition Management
- Genetic Testing Management
- Hemophilia Drug Management
- Medical Policies
- Provider-Administered Drug Policies (Excluding Oncology)
- Provider-Administered Oncology Drug Policies
- Radiation Therapy Management (RTM)
- Self-Administered Drug Policies
- Transgender Services
Blue Advantage Draft Medical Policies
To ensure that the development of Blue Advantage medical policies occurs through an open, collaborative process, we encourage physicians and other providers to submit comments about medical policies that are in the draft stage. Our current draft policies are listed below.
How to Submit Comments
We invite our participating physicians and other providers to submit scientific, evidence-based information, professional consensus opinions and other information supported by medical literature relevant to these draft policies for consideration. We accept comments for 45 days from the posting date listed on the policy.
Participating providers can comment on draft policies using one of the following methods:
Complete our medical policy feedback form
Or send comments by mail or fax to:
Medical Director's Office
Blue Cross and Blue Shield of Alabama
Post Office Box 995
Birmingham, Alabama 35298-0001
Fax: 205-220-0878
Policy # | Policy Title | View |
---|---|---|
BA-737 | Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies |